Table 2.

Background characteristics of patients living with HIV under dolutegravir with and without virological suppression.

	N	More than 50 Copies/mL		Less than 50 Copies/mL		p-Value
		n	%	n	%
Overall	305	83	27.2	222	72.8
Age						0.140
18–24	29	10	34.5	19	65.5
25–34	87	16	18.4	71	81.6
35–49	133	42	31.6	91	68.4
50–73	56	15	26.8	41	73.2
Sex						0.688
Female	219	61	27.9	158	72.1
Male	86	22	25.6	64	74.4
Education						0.802
None/Primary	195	54	27.7	141	72.3
Secondary/Tertiary	110	29	26.4	81	73.6
Marital status						0.435
Living alone	180	46	25.6	134	74.4
In Union	125	37	29.6	88	70.4
Ethnic group						0.0106
Nilotic	157	34	21.7	123	78.3
Bantu	72	22	30.6	50	69.4
Semi-Bantu	58	17	29.3	41	70.7
Sudanese	18	10	55.6	8	44.4
Residence						0.362
Urban	288	80	27.8	208	72.2
Rural	17	3	17.6	14	82.4
Creatinine						0.002
Normal	233	53	22.7	180	77.3
Abnormal	72	30	41.7	42	58.3
Stage						0.033
I and II	159	35	22.0	124	78.0
III and IV	146	48	32.9	98	67.1
Tobacco consumption						0.540
No	239	67	28.0	172	72.0
Yes	66	16	24.2	50	75.8
Status of treatment at baseline						0.814
Under ART before inclusion	220	58	26.4	162	73.6
Self-reported naïve patients with baseline VL < 50 copies/mL	52	16	30.8	36	69.2
Self-reported naïve patients with baseline VL ≥ 50 copies/mL	33	9	27.3	24	72.7
Viral load at baseline						0.002
<1000 copies/mL	224	50	22.3	174	77.7
≥1000 copies/mL	81	33	40.7	48	59.3
Exposition time under DTG-based regimen in months						0.057
6 to 7	98	26	26.5	72	73.5
8 to 9	49	7	14.3	42	85.7
10 to 12	158	50	31.6	108	68.4